Organogenesis (NASDAQ:ORGO)‘s stock had its “buy” rating reiterated by stock analysts at BTIG Research in a note issued to investors on Sunday, AnalystRatings.com reports. They presently have a $12.00 target price on the stock. BTIG Research’s price target points to a potential upside of 71.18% from the stock’s current price.
The analysts wrote, “We maintain our Buy rating and $12 PT on shares of ORGO following 1Q19 results. ORGO topped expectations across the board, with rev. of $57.1M beating BTIG/Consensus estimates of $50.6M/$52.6M bolstered by strength in PuraPly and Surgical & Sports Medicine (S&SM). FY19 guidance was raised by ~$2M (at the midpoint) ($248M-$259M to $249M-$262M) on the back of improved expectations in Surgical & Sports Medicine ($29.5M- $31.0M to $30M-$33M) and despite mfg. issues related to Affinity. We view guidance as a reflection of conservatism but confidence in underlying business fundamentals from increased rep growth, account growth, and further account penetration.””
A number of other equities research analysts also recently commented on the company. Credit Suisse Group started coverage on Organogenesis in a research report on Thursday, May 2nd. They issued an “outperform” rating and a $9.00 price objective for the company. Oppenheimer started coverage on Organogenesis in a research report on Wednesday, April 17th. They issued an “outperform” rating and a $11.00 price objective for the company. CIBC started coverage on Organogenesis in a research report on Wednesday, April 17th. They issued an “outperform” rating and a $11.00 price objective for the company. Finally, SunTrust Banks started coverage on Organogenesis in a research report on Thursday, April 11th. They issued a “buy” rating and a $11.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Organogenesis presently has an average rating of “Buy” and a consensus price target of $10.80.
Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.05). The firm had revenue of $57.12 million during the quarter, compared to the consensus estimate of $55.12 million. As a group, research analysts predict that Organogenesis will post -0.24 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Organogenesis stock. California Public Employees Retirement System acquired a new stake in Organogenesis Holdings Inc. (NASDAQ:ORGO) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 26,936 shares of the company’s stock, valued at approximately $202,000.
Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.
Featured Article: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.